Patents by Inventor Cedric Francois

Cedric Francois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11338013
    Abstract: In some aspects, the present invention provides certain combination therapies comprising compstatin analogs.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: May 24, 2022
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventor: Cedric Francois
  • Patent number: 11291407
    Abstract: In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: April 5, 2022
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 11292815
    Abstract: In some aspects, the present invention provides compositions and methods (e.g. methods of treating, preventing, making, etc.) comprising compstatin analogs. In some embodiments, compstatin analogs comprise a linear PEG moiety having a molecular weight of 40 kDa and coupled to each of two compstatin analog moieties; wherein each compstatin analog moiety is a CA28-AEEAc-Lys moiety, the linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate and each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH-CH2CH2OCH2CH2OCH2-C(?O)]-Lys-NH2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 5, 2022
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Publication number: 20220088131
    Abstract: In some aspects, provided herein is a method of enhancing production of interleukin-17 (IL-17), interferon gamma (IFN-?), or both by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing Th1 and/or Th17 responses by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing production of interleukin-6 (IL-6), interleukin 1 beta (IL-1?), or both by a mammalian T cell or monocyte, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of decreasing suppressive activity of a T regulatory cell, e.g., a natural regulatory T (nTreg) cell, the method comprising contacting a Treg cell, e.g., an nTreg cell, with an inhibitor of C5L2.
    Type: Application
    Filed: June 22, 2021
    Publication date: March 24, 2022
    Inventors: Claudia Kemper, Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Publication number: 20220040254
    Abstract: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.
    Type: Application
    Filed: April 20, 2021
    Publication date: February 10, 2022
    Inventors: Cedric Francois, Pascal Deschatelets
  • Publication number: 20220020458
    Abstract: Using a centralized system, it is possible to allow multiple disparate health care providers to gain a complete view of data regarding a patient's health and health care. Data accessible through such a central system can also be made available for researchers after being de-identified. Data in such a central system can not only include data culled from traditional physical and electronic medical records, but can also include data from distributed diagnostic devices, such as fitness trackers and consumer diagnostic equipment. Such a central system could potentially be accessed through applications made available to patients and health care providers and, in implementations where they are present, such applications could also be used for other purposes, such as performing interactive health evaluations and making recommendations of actions to take to maintain or restore a user's health.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 20, 2022
    Inventors: Cedric Francois, Gaurav Bazaz, Patrick White
  • Publication number: 20220005572
    Abstract: An application may be used to assist a patient in implementing an opioid taper. Such an application may determine levels of a cannabinoid compound that could help facilitate the patient's taper. This may include receiving information from and/or about the patient, and then using that information to determine a level of a cannabinoid compound that would be appropriate for the patient. Various other functionality, such as providing messages, recommending changes to an opioid prescription, and/or tracking a patient's progress in an opioid taper may also be provided.
    Type: Application
    Filed: September 20, 2021
    Publication date: January 6, 2022
    Inventors: Cedric Francois, Brent Zettl
  • Publication number: 20210401997
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: April 29, 2021
    Publication date: December 30, 2021
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Patent number: 11152114
    Abstract: Using a centralized system, it is possible to allow multiple disparate health care providers to gain a complete view of data regarding a patient's health and health care. Data accessible through such a central system can also be made available for researchers after being de-identified. Data in such a central system can not only include data culled from traditional physical and electronic medical records, but can also include data from distributed diagnostic devices, such as fitness trackers and consumer diagnostic equipment. Such a central system could potentially be accessed through applications made available to patients and health care providers and, in implementations where they are present, such applications could also be used for other purposes, such as performing interactive health evaluations and making recommendations of actions to take to maintain or restore a user's health.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: October 19, 2021
    Assignee: ZYUS LIFE SCIENCES US LTD.
    Inventors: Gaurav Bazaz, Patrick White, Cedric Francois
  • Publication number: 20210292368
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
    Type: Application
    Filed: March 17, 2021
    Publication date: September 23, 2021
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 11101026
    Abstract: In some aspects, the present disclosure provides a computer program product for assembling a database comprising electronic data modules, which may be electronic medical records (EMRs). The present disclosure can also be used for purposes such as implementing a system in which physicians and patents can be provided with applications that they can use to confirm that various disease related events have taken place. This can be performed using active diagnosis modules (ADMs) comprising schedules of events. These ADMs and their events can also be used to populate a database which can be used for purposes such as identifying, recruiting and tracking participants in clinical trials.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 24, 2021
    Assignee: Zyus Life Sciences US Ltd.
    Inventors: Cedric Francois, Gaurav Bazaz, Alec Machiels, Pascal Deschatelets, Monica Gerber
  • Patent number: 11069430
    Abstract: Using a centralized system, it is possible to allow multiple disparate health care providers to gain a complete view of data regarding a patient's health and health care. Data accessible through such a central system can also be made available for researchers after being de-identified. Data in such a central system can not only include data culled from traditional physical and electronic medical records, but can also include data from distributed diagnostic devices, such as fitness trackers and consumer diagnostic equipment. Such a central system could potentially be accessed through applications made available to patients and health care providers and, in implementations where they are present, such applications could also be used for other purposes, such as performing interactive health evaluations and making recommendations of actions to take to maintain or restore a user's health.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: July 20, 2021
    Assignee: Zyus Life Sciences US Ltd.
    Inventors: Cedric Francois, Gaurav Bazaz, Patrick White
  • Publication number: 20210198320
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Application
    Filed: December 18, 2020
    Publication date: July 1, 2021
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Patent number: 11040107
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 22, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Patent number: 11013782
    Abstract: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 25, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 11001610
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 11, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 10986993
    Abstract: The subject matter of the disclosure relates generally to a MEMS-based position-sensing system and lenses, for example, contact lenses and intra-ocular lenses, manufactured with the position-sensing system employing one or more angular and/or linear accelerometers and/or pressure transducers and methods for detecting position and motion of an eyeball and/or head utilizing the position-sensing contact lenses.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Inventors: Cedric Francois, Mark Salman Humayun
  • Publication number: 20210107944
    Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.
    Type: Application
    Filed: June 9, 2020
    Publication date: April 15, 2021
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 10941184
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Publication number: 20210032289
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: June 25, 2020
    Publication date: February 4, 2021
    Inventors: Cedric Francois, Pascal Deschatelets